Taurodeoxycholic acid sodium hydrate Sodium taurodeoxycholate monohydrate|cas:110026-03-4|西域试剂

Taurodeoxycholic acid sodium hydrate Sodium taurodeoxycholate monohydrate,98.0%

产品编号：Bellancom-B1899A| CAS NO：110026-03-4| 分子式：C₂₆H₄₆NNaO₇S| 分子量：539.70

Taurodeoxychloic Acid (sodium hydrate) 通过阻断钙介导的凋亡通路和 Caspase-12的活化来阻止细胞凋亡。Taurodeoxychloic Acid (sodium hydrate) 被用于多种研究，如原发性胆汁性肝硬化 (PBC)，胰岛素抵抗，淀粉样变性，囊性纤维化，胆汁淤积和肌萎缩侧索硬化症。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-B1899A		￥500.00	杭州北京（现货）
Bellancom-B1899A		￥1400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Taurodeoxycholic acid sodium hydrate Sodium taurodeoxycholate monohydrate

产品介绍

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) 是一种胆汁酸，是由肝脏中的胆固醇合成的两亲性表面活性剂分子。除 TGR5 通路外，Taurodeoxycholic acid sodium hydrate 还激活 S1PR2 通路。

生物活性

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.

体外研究

The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals.
Taurodeoxycholate inhibits the binding of N-³H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC₅₀ of 170 µM.
Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation.
Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	IEC-6 and caco-2 cells
Concentration:	0, 0.05, 0.50, and 1.00 mM
Incubation Time:	1, 2, 4 and 6 days
Result:	Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.

Cell Cycle Analysis

Cell Line:	IEC-6 cells
Concentration:	0, 0.05, 0.50, and 1.00 mM
Incubation Time:	24 h
Result:	Significantly increased cells in S phase and decreased cells in G1-phase.

Western Blot Analysis

Cell Line:	IEC-6 cells
Concentration:	0.5 mM
Incubation Time:	1 and 6 days
Result:	Significantly increased c-myc protein expression.

体内研究
(In Vivo)

Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:	0.5 mg/kg
Administration:	Intravenous injection, 30 min or 24 h after LPS injection
Result:	Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.

体内研究

Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:	0.5 mg/kg
Administration:	Intravenous injection, 30 min or 24 h after LPS injection
Result:	Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.

体内研究

Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:	0.5 mg/kg
Administration:	Intravenous injection, 30 min or 24 h after LPS injection
Result:	Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (231.61 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8529 mL	9.2644 mL	18.5288 mL
5 mM	0.3706 mL	1.8529 mL	3.7058 mL
10 mM	0.1853 mL	0.9264 mL	1.8529 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (37.06 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.85 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.85 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.85 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984. [Content Brief]

. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

危害码 (欧洲)	Xn: Harmful;
风险声明 (欧洲)	22-37
安全声明 (欧洲)	22-36
WGK德国	3

Taurodeoxycholic acid sodium hydrate Sodium taurodeoxycholate monohydrate,98.0%

Taurodeoxycholic acid sodium hydrate Sodium taurodeoxycholate monohydrate

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询